MnetTV          Digital Library

Search Manufacturing.net
Today in Manufacturing.Net

Resources
Bookstore
Career Center
Events Calendar
Links
White Papers
Digital Library

Time to Market

News
Featured Articles
Financial News
Global Manufacturing
Government News
Mergers & Acquisitions
News Archive
People in the News

Free White Papers

Market Sectors
Aerospace
Automotive/Transportation
Chemical/Petroleum
Food/Beverage
Medical
Metals
Pharmaceuticals/Biotech
Plastics/Rubber
Other Manufacturing

Amazon

Industry Focus
Design & Development
Electrical & Electronics
Energy
Environmental
Facilities & Operations
Labor Relations
Manufacturing Technology
Materials
Quality
Safety
Supply Chain

Career Center
CareerBuilder.com


About Us
Editorial Contacts
Advertise with Us

Our Partner Sites
Chem.Info
ECN
Food Manufacturing
IMPO (Industrial Maintenance & Plant Operation)
Medical Design Technology
Pharmaceutical Processing
Product Design & Development
R & D Magazine
Wireless Design & Development
Wireless Week





Advertise with Mnet



Pfizer Settles Pollution Violations

Manufacturing.Net - June 23, 2008

Printer Friendly     E-mail to a Colleague


NEW HAVEN, Conn. (AP) -- Pfizer Inc., the world's largest drug maker, has agreed to pay a $975,000 civil penalty to resolve alleged violations of the Clean Air Act at its former manufacturing plant in Groton, federal officials announced Monday.

The U.S. Department of Justice and the Environmental Protection Agency said the settlement is the first of its type in federal court under regulations designed to control the emissions of hazardous air pollutants from pharmaceutical manufacturing operations.

"We will not wait to enforce the law until after a catastrophe occurs," said Ronald J. Tenpas, assistant attorney general for the Justice Department's Environment and Natural Resources Division.

"Penalties such as this one compel the industry's close attention and rigorous implementation of the leak detection requirements to prevent the escape of harmful air pollutants that can endanger the public," he said.

Officials said the alleged violations occurred between October 2002 and December 2005 and resulted from a failure of Pfizer's leak detection and repair program.

The specific violations, associated with the production of bulk pharmaceutical materials, included a failure to properly conduct pressure tests to identify leaks, repair leaks before startup, equip open-ended lines with a cap or other seal and document leak tests to establish full compliance with the requirements, officials said.

Pfizer certifies in the agreement that the violations have been corrected. But officials said the violations undermined EPA's ability to determine compliance, which presented the risk of excess emissions of hazardous air pollutants from leaks that were not timely detected and repaired.

The Groton facility ceased pharmaceutical manufacturing in January.

A message seeking comment was left with Pfizer.

During its production of pharmaceutical-grade chemicals, Pfizer used substances such as methanol, hydrogen chloride, methylene chloride, MTBE, hexane, toluene and others that the EPA classifies as hazardous air pollutants.

Pfizer, a publicly traded corporation, operates about 80 manufacturing plants worldwide where it makes health care products relating to human and animal health.


Printer Friendly     E-mail to a Colleague




 

     










THIS WEEK'S MOST
READ NEWS ITEMS

Chemicals/Petroleum

Hexion Turns Down Financing From Huntsman

Westlake Chemical Building Plant In Louisiana

One Dead, One Injured After Chemical Plant Blast


Plastics/Rubber

Chemical Safety Board Probes Goodyear Plant Blast

Albemarle Raises Plastic Additive Prices

AEP Industries Buying Plastic Film Unit

Pharmaceuticals/Biotech

Drugmaker UCB Cutting 2,000 Jobs

Otsuka Pharmaceutical Purchases Czech Firm

King Pharmaceuticals Offers Alpharma $1.4 Billion
News Video